Cargando…

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19()

Detalles Bibliográficos
Autores principales:	Huang, Ching-Tai, Hsu, Shao-Yun, Chang, Ko-Wei, Huang, Chung-Guei, Yang, Cheng-Ta, Cheng, Ming-Huei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Letter to the Editors-in-Chief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834633/ https://www.ncbi.nlm.nih.gov/pubmed/32810772 http://dx.doi.org/10.1016/j.thromres.2020.07.056

Ejemplares similares

Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia()
por: Huang, Ching-Tai, et al.
Publicado: (2021)

Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients
por: Preti, Paola S., et al.
Publicado: (2021)

Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group
por: Ray, Joel G., et al.
Publicado: (2021)

Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination
por: Langerak, T., et al.
Publicado: (2022)

Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination
por: Franchini, Massimo, et al.
Publicado: (2021)

Fatal intracranial hemorrhage in patient with thrombocytopenia and positive HIT antibodies after vaccination with ChAdOx1 nCoV-19 - VITT without thrombosis?
por: Medić, Marijana Grgić, et al.
Publicado: (2022)

COVID-19 associated pulmonary thrombosis
por: van Nieuwkoop, C.
Publicado: (2020)

Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study
por: Rodríguez, Carmen, et al.
Publicado: (2021)

The long haul COVID-19 arterial thrombosis
por: Borrelli, Maria Pia, et al.
Publicado: (2022)

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis
por: Moll, Matthew, et al.
Publicado: (2021)

Portal vein thrombosis in a patient with COVID-19
por: Franco-Moreno, A., et al.
Publicado: (2020)

Detection of anti-GPIbα autoantibodies in a case of immune thrombocytopenia following COVID-19 vaccination
por: Nakamura, Takayuki, et al.
Publicado: (2022)

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021)

Heparin induced thrombocytopenia-type 2
por: Majeed, Tanveer A.
Publicado: (2010)

In situ immune-mediated pulmonary artery thrombosis and Covid-19 pneumonitis
por: Mandal, Amit K.J., et al.
Publicado: (2021)

Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways
por: Dalan, Rinkoo, et al.
Publicado: (2021)

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era
por: Qin, Wei, et al.
Publicado: (2021)

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study
Publicado: (2021)

Impact of blood type on thrombosis and disease severity in adult COVID-19 patients()
por: Rao, Shivani, et al.
Publicado: (2021)

Safety of COVID-19 vaccination in patients with previous cerebral venous sinus thrombosis
por: Gil-Díaz, Aída, et al.
Publicado: (2022)

In situ pulmonary thrombosis in patients with COVID-19 pneumonia: different phenotypes may exist
por: Wang, Lan, et al.
Publicado: (2020)

COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic
por: Parks, Anna L., et al.
Publicado: (2020)

Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care
por: Thomas, W., et al.
Publicado: (2020)

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy
por: Daughety, Molly M., et al.
Publicado: (2020)

D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19
por: Stawiarski, Kristin, et al.
Publicado: (2021)

Re: Heparin-induced thrombocytopenia – Type 2
por: Yagnik, Vipul D.
Publicado: (2011)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020)

Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: A multicenter case-control study
por: Smit, Jasper M., et al.
Publicado: (2021)

Heparin: Heparin-induced thrombocytopenia and thrombosis: case report
Publicado: (2020)

Heparin-induced thrombocytopenia in a patient with colon cancer
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Heparin-induced thrombocytopenia in a patient with colon cancer
por: Koul, Ajaz Nabi, et al.
Publicado: (2013)

Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg
por: Pizzolo, Francesca, et al.
Publicado: (2020)

Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research
por: Lämmle, Bernhard, et al.
Publicado: (2021)

The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
por: May, Jori E., et al.
Publicado: (2020)

How to improve the management of a patient with heparin-induced thrombocytopenia?
por: Undas, Anetta
Publicado: (2019)

Response to The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
por: Riker, Richard R., et al.
Publicado: (2020)

Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019
por: Ogawa, Yoshihiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gtlifkuhfv3nd2h4nj2mc5rpij